Form 4: Tyra Biosciences Director Acquires Stock Options

Tyra Biosciences Director Robert J. More acquired stock options for 13,160 shares of common stock under the company's Non-Employee Director Compensation Program.

Summary

• Robert J. More, a Director at Tyra Biosciences, Inc., was granted stock options on May 28, 2026.
• The options are for 13,160 shares of common stock with an exercise price of $32.68 per share.
• These options are part of the Issuer's Non-Employee Director Compensation Program.
• Vesting occurs monthly, with 1/12th of the shares vesting each month following the grant date.
• Any unvested portion will vest on the date of the next annual stockholder meeting if it occurs before the first anniversary of the grant date, provided continuous service is maintained.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic update for the company.

Positives

• Director More's acquisition of stock options aligns his interests with those of other shareholders, potentially incentivizing long-term company performance.
• The stock options are granted under a formal compensation program, indicating established governance practices for director remuneration.

Negatives

• The filing only details the grant of options and does not provide information on the company's current financial performance or operational status, which could be viewed negatively by investors seeking broader updates.

Risks

• The value of the stock options is subject to market fluctuations and the future performance of Tyra Biosciences' stock price.
• Vesting is contingent on continuous service, meaning the director could forfeit unvested options if they leave the company before the vesting dates.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the director's continued service. The vesting schedule indicates a phased release of equity over time.

Management Comments

• "The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program."
• "1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant."
• "In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice across the biotechnology and pharmaceutical industries, serving as a standard incentive to align executive and director interests with shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The alignment of director interests through stock options may positively influence long-term company strategy and performance.
• Employees: While not directly impacted, the company's ability to attract and retain qualified directors through compensation packages can indirectly benefit employees by ensuring strong leadership.
• Management: The filing is a routine disclosure related to director compensation, not directly impacting day-to-day management operations.

Next Steps

• Monthly vesting of stock options for Robert J. More.
• Potential accelerated vesting of remaining unvested options on the date of the next annual stockholder meeting.
• Continued service by Robert J. More to the Issuer through each vesting date.

Key Dates

Keywords

Tyra Biosciences, Form 4, Stock Options, Director Compensation, Insider Trading, SEC Filing, Equity Award, Vesting Schedule